Gilead Sciences, Inc. (NASDAQ:GILD) will participate at the 28th Annual JP Morgan Healthcare Conference on Monday, January 11. The company will be represented by Gilead Chairman and Chief Executive Officer John Martin, PhD. He will begin his presentation at 9:30 am PT that morning to discuss an overview of the company. Interested parties may listen to a live webcast of the event online at http://www.gilead.com/. Listeners are encouraged to visit the site fifteen minutes early to allow ample time to download and install any necessary audio software.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Canada, France, Germany, Greece, Ireland, Italy, New Zealand, Portugal, Spain, Switzerland, Turkey, United Kingdom, and United States. Its commercial team promotes Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis, and Flolan through direct field contact with physicians, hospitals, clinics, and other healthcare providers. Gilead’s corporate partner, Astellas Pharma, Inc. (Astellas), promotes and sells AmBisome in the United States, Canada, Europe, Australia, and New Zealand. In May 2008, the Company acquired Navitas Assets, LLC’s. In April 2009, the Company announced the completion of its acquisition of CV Therapeutics, Inc.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
